secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2022-09-26T23:59:59+00:00
Accession:  0001493152-22-026752
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo reports positive interim Phase 2 data for ANEB-001 in acute cannabinoid intoxication
--------------------------------------------------------------------------------

- Part B: 21mg THC challenge; 10mg or 30mg ANEB-001 significantly reduced VAS feeling high (p<0.001), improved alertness (p<0.01), and reduced body sway (p<0.01) vs placebo.
- Placebo group: 100% of subjects met VAS threshold for feeling high; only 1 subject per active dose group met threshold.
- Safety: adverse events mild/transient except two moderate dizziness cases in Cohort 1 likely THC-attributable.
- Company continuing Part B, enrolling third cohort; collaborating with FDA MIDD group on PK/PD model to optimize dosing for ACI.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315222026752/0001493152-22-026752-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315222026752/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-026752

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer